uniQure's FDA U-Turn Keeps AMT-130 at 'Hold'-but Huntington's Approval Odds Just Improved

FDA feedback improved the path, but not enough to upgrade

This is genuine de-risking, not approval, which is why Hold remains the disciplined stance. In March, the FDA said it cannot agree that Phase I/II data compared to an external control were sufficient and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. Now, after a Type B meeting, the agency says three-year data from the ongoing phase 1/2 program may support an accelerated approval submission, with a BLA as early as the third quarter of 2026. That meaningfully narrows the regulatory path.

Why that matters financially: the market now has a more plausible route to monetization from the existing clinical dataset, rather than needing to assume a brand-new study would have to rescue the case. In valuation terms, that improves the expected value of the asset before the possibility is fully priced in.

There is still a gate to clear. The FDA wants alignment on the confirmatory study prior to filing, and Huntington's still has no approved treatments that currently slow disease progression. That backdrop supports regulatory flexibility, but it does not remove execution risk. So the setup is better, yet still not certain enough to move beyond Hold.

Why the FDA reversal matters for AMT-130's value

This matters more than a routine positive update because the FDA has changed where uniQure has to win. Huntington's may affect only about 75,000 people in the U.S., Europe and UK, but that is exactly why the business logic can still work. In a market this small, a therapy that offers durable disease modification does not need blockbuster-scale volume to create a valuable piece of the business. AMT-130 is designed as a one-time neurosurgical administration aimed at reducing production of the mutant huntingtin protein, and Huntington's still has no approved treatments that currently slow disease progression. The real question is whether a one-and-done therapy can secure a disease-modifying claim.

The value switch is now the confirmatory study

The earlier risk was that uniQure might need a brand-new, make-or-break study just to build an approval case from scratch. The new feedback says that is no longer the default position. That does not remove the hardest work; it shifts it to a more precise battleground: the confirmatory study. The FDA has asked for alignment on that trial design and flagged the potential use of a concurrent standard-of-care control arm rather than a sham procedure. For investors, that is the real value switch. A cleaner evidence path can improve expected value faster than a headline because it reduces the chance that the commercial case depends on an entirely new execution bet.

What investors should watch in trial design

The key trial-design outcomes to watch now are:

• whether the FDA continues to support submission on the existing phase 1/2 dataset;
• whether the confirmatory study can move away from sham control toward a standard-of-care design; and
• whether timelines for finalizing that design stay on track.

QURE still looks like a wait-and-verifier

From here, QURE is a wait-and-verifier, not a chase. The FDA has improved the path, but the drug has not been approved and the application has not been filed. For investors, that distinction matters. A better road is not the same thing as clearing the finish line.

What "Hold" means in practice

Hold does not mean the story is broken. It means the smart move is to let the next milestones do the work. The next catalyst window is management's commitment to finalize details of the confirmatory trial with the FDA in the coming months, after the agency said it may accept three-year data from the ongoing phase 1/2 program for an accelerated approval submission. If those discussions stay on that track, the stock can keep repricing. If they slip, the upside can vanish just as quickly.

What would break the Hold

The clearest invalidation signals are:

• the BLA actually files, or
• the confirmatory study path gets muddy enough that investors start doubting the existing data can carry the case.

Until then, the disciplined stance is to wait for proof of execution, not just a better narrative.